The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma
© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies..
ABSTRACT: Plasmablastic lymphoma (PBL) is a rare and aggressive non-Hodgkin lymphoma associated with immunodeficiency, characterized by uncertain treatment approaches and an unfavorable prognosis. We conducted a multicenter, international, retrospective cohort study, aiming to characterize the clinical features, risk factors, and outcomes of patients with PBL. Data were collected from 22 institutions across 4 countries regarding patients diagnosed with PBL between 1 January 1999 and 31 December 2020. Survival risk factors were analyzed using both univariate and multivariate regression models. Overall survival (OS) was calculated using Kaplan-Meier statistics. First-line treatment regimens were stratified into standard- and higher-intensity regimens, and based on whether they incorporated a proteasome inhibitor (PI). A total of 281 patients (median age, 55 years) were included. Immunodeficiency of any kind was identified in 144 patients (51%), and 99 patients (35%) had HIV-positive results. The 5-year OS for the entire cohort was 36% (95% confidence interval, 30%-42%). In multivariate analysis, inferior OS was associated with Epstein-Barr virus-negative lymphoma, poor performance status, advanced stage, and bone marrow involvement. In an independent univariate analysis, the international prognostic index was associated with OS outcomes. Neither immunosuppression nor HIV infection, specifically, influenced OS. Among patients treated with curative intent (n = 234), the overall response rate was 72%. Neither the intensity of the treatment regimen nor the inclusion of PIs in first-line therapy was associated with OS. In this large retrospective study of patients with PBL, we identified novel risk factors for survival. PBL remains a challenging disease with poor long-term outcomes.
| Errataetall: |
CommentIn: Blood. 2024 Jan 11;143(2):101-102. - PMID 38206643 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:143 |
|---|---|
| Enthalten in: |
Blood - 143(2024), 2 vom: 11. Jan., Seite 152-165 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Di Ciaccio, Pietro R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 12.01.2024 Date Revised 24.03.2024 published: Print CommentIn: Blood. 2024 Jan 11;143(2):101-102. - PMID 38206643 Citation Status MEDLINE |
|---|
| doi: |
10.1182/blood.2023021348 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363249931 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363249931 | ||
| 003 | DE-627 | ||
| 005 | 20240324234826.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood.2023021348 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1344.xml |
| 035 | |a (DE-627)NLM363249931 | ||
| 035 | |a (NLM)37832030 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Di Ciaccio, Pietro R |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.01.2024 | ||
| 500 | |a Date Revised 24.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Blood. 2024 Jan 11;143(2):101-102. - PMID 38206643 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies. | ||
| 520 | |a ABSTRACT: Plasmablastic lymphoma (PBL) is a rare and aggressive non-Hodgkin lymphoma associated with immunodeficiency, characterized by uncertain treatment approaches and an unfavorable prognosis. We conducted a multicenter, international, retrospective cohort study, aiming to characterize the clinical features, risk factors, and outcomes of patients with PBL. Data were collected from 22 institutions across 4 countries regarding patients diagnosed with PBL between 1 January 1999 and 31 December 2020. Survival risk factors were analyzed using both univariate and multivariate regression models. Overall survival (OS) was calculated using Kaplan-Meier statistics. First-line treatment regimens were stratified into standard- and higher-intensity regimens, and based on whether they incorporated a proteasome inhibitor (PI). A total of 281 patients (median age, 55 years) were included. Immunodeficiency of any kind was identified in 144 patients (51%), and 99 patients (35%) had HIV-positive results. The 5-year OS for the entire cohort was 36% (95% confidence interval, 30%-42%). In multivariate analysis, inferior OS was associated with Epstein-Barr virus-negative lymphoma, poor performance status, advanced stage, and bone marrow involvement. In an independent univariate analysis, the international prognostic index was associated with OS outcomes. Neither immunosuppression nor HIV infection, specifically, influenced OS. Among patients treated with curative intent (n = 234), the overall response rate was 72%. Neither the intensity of the treatment regimen nor the inclusion of PIs in first-line therapy was associated with OS. In this large retrospective study of patients with PBL, we identified novel risk factors for survival. PBL remains a challenging disease with poor long-term outcomes | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Polizzotto, Mark N |e verfasserin |4 aut | |
| 700 | 1 | |a Cwynarski, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Gerrie, Alina S |e verfasserin |4 aut | |
| 700 | 1 | |a Burton, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Bower, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Kuruvilla, John |e verfasserin |4 aut | |
| 700 | 1 | |a Montoto, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a McKay, Pam |e verfasserin |4 aut | |
| 700 | 1 | |a Fox, Christopher P |e verfasserin |4 aut | |
| 700 | 1 | |a Milliken, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Jiamsakul, Awachana |e verfasserin |4 aut | |
| 700 | 1 | |a Osborne, Wendy |e verfasserin |4 aut | |
| 700 | 1 | |a Collins, Graham P |e verfasserin |4 aut | |
| 700 | 1 | |a Manos, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Linton, Kim M |e verfasserin |4 aut | |
| 700 | 1 | |a Iyengar, Sunil |e verfasserin |4 aut | |
| 700 | 1 | |a Kassam, Shireen |e verfasserin |4 aut | |
| 700 | 1 | |a Limei, Michelle Poon |e verfasserin |4 aut | |
| 700 | 1 | |a Kliman, David |e verfasserin |4 aut | |
| 700 | 1 | |a Wong Doo, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Watson, Anne-Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Fedele, Pasquale |e verfasserin |4 aut | |
| 700 | 1 | |a Yannakou, Costas K |e verfasserin |4 aut | |
| 700 | 1 | |a Hunt, Stewart |e verfasserin |4 aut | |
| 700 | 1 | |a Ku, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Sehn, Laurie H |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Renshaw, Hanna |e verfasserin |4 aut | |
| 700 | 1 | |a Maxwell, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Qin |e verfasserin |4 aut | |
| 700 | 1 | |a Dhairyawan, Rageshri |e verfasserin |4 aut | |
| 700 | 1 | |a Ferguson, Graeme |e verfasserin |4 aut | |
| 700 | 1 | |a Pickard, Keir |e verfasserin |4 aut | |
| 700 | 1 | |a Painter, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Thakrar, Nisha |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Kevin W |e verfasserin |4 aut | |
| 700 | 1 | |a Hamad, Nada |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d 1946 |g 143(2024), 2 vom: 11. Jan., Seite 152-165 |w (DE-627)NLM000014761 |x 1528-0020 |7 nnns |
| 773 | 1 | 8 | |g volume:143 |g year:2024 |g number:2 |g day:11 |g month:01 |g pages:152-165 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/blood.2023021348 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 143 |j 2024 |e 2 |b 11 |c 01 |h 152-165 | ||